 | |
| Clinical data | |
|---|---|
| ATC code |
|
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider | |
| UNII | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C16H19N3O3 |
| Molar mass | 301.346 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
HIOC is asmall-moleculeagent which acts as aselectiveTrkB receptoragonist (active at at least 100 nM; prominent activation at 500 nM).[1][2][3] It was derived fromN-acetylserotonin (NAS).[2][3][4] Relative to NAS, HIOC possesses greater potency and a longerhalf-life (~30 min or less for NAS in rats, while HIOC is still detectable up to 24 hours after administration to mice; ~4 hour half-life for HIOC in mouse brain tissues).[2][3] It is described as producing long-lasting activation of the TrkB receptor and downstreamsignaling kinases associated with the receptor.[2] HIOC issystemically active and is able to penetrate theblood-brain-barrier.[2] Inanimal studies, HIOC was found to robustly protect againstglutamate-inducedexcitotoxicity, an action which was TrkB-dependent.[3]
Achemical synthesis of HIOC was published in 2015.[5]
 | Thisdrug article relating to thenervous system is astub. You can help Wikipedia byexpanding it. |
